| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SGCa |
| Uniprot No | Q16586 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-387aa |
| 氨基酸序列 | MAETLFWTPLLVVLLAGLGDTEAQQTTLHPLVGRVFVHTLDHETFLSLPE HVAVPPAVHITYHAHLQGHPDLPRWLRYTQRSPHHPGFLYGSATPEDRGL QVIEVTAYNRDSFDTTRQRLVLEIGDPEGPLLPYQAEFLVRSHDAEEVLP STPASRFLSALGGLWEPGELQLLNVTSALDRGGRVPLPIEGRKEGVYIKV GSASPFSTCLKMVASPDSHARCAQGQPPLLSCYDTLAPHFRVDWCNVTLV DKSVPEPADEVPTPGDGILEHDPFFCPPTEAPDRDFLVDALVTLLVPLLV ALLLTLLLAYVMCCRREGRLKRDLATSDIQMVHHCTIHGNTEELRQMAAS REVPRPLSTLPMFNVHTGERLPPRVDSAQVPLILDQH |
| 预测分子量 | 69 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SGCa重组蛋白的3篇参考文献示例(注：文献为假设性示例，实际引用时需核实)：
---
1. **文献名称**: *Expression and Purification of Recombinant SGCa in E. coli for Calcium-Binding Studies*
**作者**: Zhang, L., et al.
**摘要**: 本研究报道了SGCa基因在大肠杆菌中的高效重组表达及纯化方法，通过体外实验验证了其钙离子结合能力，并分析了pH和温度对蛋白稳定性的影响。
2. **文献名称**: *Structural Insights into SGCa by X-ray Crystallography: Implications for Disease-Related Mutations*
**作者**: Lee, H., et al.
**摘要**: 通过X射线晶体学解析了SGCa的三维结构，揭示了其钙离子结合域的关键氨基酸残基，并探讨了与遗传性疾病相关的突变位点对蛋白功能的影响。
3. **文献名称**: *Development of a High-Throughput Screening Assay Using Recombinant SGCa for Drug Discovery*
**作者**: Smith, R., et al.
**摘要**: 基于重组SGCa蛋白开发了一种高通量药物筛选平台，用于筛选调控钙信号通路的潜在化合物，验证了其在药物开发中的应用价值。
---
如需真实文献，建议通过PubMed或Web of Science检索关键词“SGCa recombinant protein”或联系相关领域数据库获取最新研究。
SGCa recombinant protein, commonly referred to as recombinant Sarcoglycan-alpha, is a genetically engineered protein derived from the human sarcoglycan-alpha (SGCA) gene. Sarcoglycans are critical components of the dystrophin-glycoprotein complex (DGC), which stabilizes muscle cell membranes during contraction and protects against mechanical stress. Mutations in the SGCA gene are linked to limb-girdle muscular dystrophy type 2D (LGMD2D), a progressive disorder characterized by muscle weakness and degeneration.
The development of SGCa recombinant protein aims to address the functional deficiency caused by these mutations. Produced via heterologous expression systems such as mammalian cells or bacteria, the recombinant protein retains key structural and functional domains of native sarcoglycan-alpha, including transmembrane regions and extracellular binding sites. This allows it to integrate into cellular membranes and restore DGC stability in experimental models.
Research on SGCa recombinant protein focuses on therapeutic applications, including gene therapy and protein replacement strategies. It also serves as a tool for studying molecular mechanisms of muscular dystrophies, enabling investigations into protein interactions, membrane repair pathways, and disease biomarkers. Recent studies explore its potential in improving muscle function in preclinical models, highlighting its significance in translational medicine. Despite challenges in delivery and immunogenicity, advancements in protein engineering and viral vector design continue to enhance its therapeutic viability. Overall, SGCa recombinant protein represents a promising avenue for both understanding and treating sarcoglycanopathies.
×
